Size : | Price | Quantity | |
---|---|---|---|
5 mg | $56.00 | ||
25 mg | $218.00 |
MCC-950 (210826-40-7) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1.1 Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes.2 MCC-950 blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations.3 Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model).3 Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome.4 MCC-950 is a valuable new tool for exploring the pathophysiology of NLRP3.
References/Citations:
1) Laliberte et al. (2003), Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing; J. Biol. Chem., 278 16567
2) Coll et al. (2011), The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes; Clin. PLoS One, 6(12) e29539
3) Coll et al. (2015), A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease; Nat. Med., 21 248
4) Kaneko et al. (2015), Reconstituted AIM2 inflammasome in cell-free system; J. Immunol. Methods, 426 76
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
MCC-950 (210826-40-7) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1.1 Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes.2 MCC-950 blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations.3 Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model).3 Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome.4 MCC-950 is a valuable new tool for exploring the pathophysiology of NLRP3.
References/Citations:
1) Laliberte et al. (2003), Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing; J. Biol. Chem., 278 16567
2) Coll et al. (2011), The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes; Clin. PLoS One, 6(12) e29539
3) Coll et al. (2015), A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease; Nat. Med., 21 248
4) Kaneko et al. (2015), Reconstituted AIM2 inflammasome in cell-free system; J. Immunol. Methods, 426 76
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.